Ligand Pharmaceuticals Inc. (LGND)
NASDAQ · Healthcare
Ligand Pharmaceuticals Inc. Income Statement 2009–2025
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenue | 268.1M | 167.1M | 131.3M | 196.2M | 241.5M | 163.6M | 120.3M | 251.5M | 141.1M | 109.0M | 71.9M | 64.5M | 49.0M | 31.4M | 30.0M | 23.5M | 38.9M |
| Gross Profit | — | — | — | — | — | — | — | 245.1M | 135.7M | 103.4M | 66.1M | 55.4M | 43.2M | 27.8M | 25.1M | — | — |
| Profitability | |||||||||||||||||
| Operating Income | 41.0M | -22.6M | 11.9M | 3.0M | 103.9M | 37.5M | 807.1M | 163.7M | 68.1M | 43.9M | 27.3M | 19.6M | 14.9M | 193,000 | -878,000 | -29.3M | -10.0M |
| EBITDA | 74.8M | 12.6M | 48.5M | 54.6M | 154.9M | 63.2M | 825.4M | 176.5M | 79.0M | 55.2M | 30.0M | 22.3M | 17.6M | 2.9M | 1.9M | -27.1M | -5.3M |
| Net Income | 124.5M | -4.0M | 52.2M | -33.4M | 57.1M | -3.0M | 629.3M | 143.3M | 12.6M | -1.6M | 229.8M | 12.0M | 11.4M | -527,000 | 9.7M | -10.4M | -1.9M |
| Per Share Data | |||||||||||||||||
| EPS (diluted) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding (dil.) | 20M | 18M | 18M | 17M | 17M | 17M | 20M | 24M | 23M | 21M | 21M | 21M | 21M | 20M | 20M | 20M | 19M |
Ligand Pharmaceuticals Inc. Income Statement — FAQ
Ligand Pharmaceuticals Inc. (LGND) income statement over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LGND's income statement history?
The chart and table above show Ligand Pharmaceuticals Inc.'s income statement by year and by quarter, including the growth rate.